corticosteroids are the most commonly used therapeutic agents, others being chloroquine, cellulose sodium phosphate, bisphosphonates, and ketoconazole. Not all patients need treatment. Hypercalcaemia occurs in some 5-10% of cases and can be a serious complication2. In sarcoidosis 1,25 dihydroxy vitamin D is believed to be produced by macrophages3, and patients with abnormal calcium metabolism show a high rate of production, associated with increased intestinal absorption of calcium4.
The hypercalcaemia of chronic sarcoidosis tends to persist and can result in nephrocalcinosis and renal failure, though renal involvement is clinically apparent in less than 10% of patients5. Measurement of serum angiotensin converting enzyme (ACE) activity is helpful in monitoring the clinical course. Here we report a difficult case.
CASE HISTORY
In 1983 a 23-year-old woman was found to have bilateral hilar lymphadenopathy, believed to be due to sarcoidosis. This resolved without treatment. She remained symptomfree until February 1989, when she presented with erythema nodosum and arthralgia. Haemoglobin was 12.7 g/dL, erythrocyte sedimentation 21 mm in the 1st hour, adjusted serum calcium 2.30mmol/L (normal range 2.20-2.60), serum creatinine 80,mol/L (50-130), and serum ACE 173 U/L (13-54). Histology of her nodules was consistent with erythema nodosum. Chest X-ray and computed tomographic scanning showed paratracheal and hilar lymphadenopathy as well as reticulonodular infiltrates. Rheumatoid factor and antinuclear factor were both negative. Band keratopathy was noted by an ophthalmologist. Sarcoidosis was confirmed by a positive Kveim test and a mediastinal biopsy showing non-caseating granulomata. Treatment was started with prednisolone (40mg reducing to 15 mg) and indomethacin 75 mg thrice daily. 18 months later, while she was taking indomethacin and 15 mg prednisolone, her adjusted calcium rose to 2.75 mmol/L and creatinine was raised at 236,umol/L. Prednisolone was increased to 40mg for 4 weeks followed by 30mg for a further 4 weeks. After 8 weeks of high-dose corticosteroids, serum ACE was 36 U/L, adjusted calcium 2.43 mmol/L, and creatinine 125pmol/L. She continued on 15mg of prednisolone over the following 11 months but serum ACE and adjusted calcium increased to 167 U/L and 3.47 mmol/L, respectively. High-dose corticosteroids were tried again. After 1 month her adjusted calcium was 2.55 mmol/L and creatinine 231 ymol/L. Haemoglobin fell to 8.7 g/dL. Plasma B12, red cell folate, iron studies and a bone marrow aspirate were normal. Over the next 3 months adjusted calcium rose to 3.25 mmol/L and creatinine to 266 pmol/L despite prescription of 30mg prednisolone daily. An ultrasound scan of her kidneys revealed bilateral renal parenchymal disease with calculi.
A renogram showed evidence of incipient renal failure, both kidneys functioning poorly and an effective renal plasma flow of 20 mL/min. Parathyroid hormone was suppressed at 0.9 pmol/L (normal 1.1-6.9). Alkaline phosphatase was within the reference range. The patient was admitted for saline diuresis, intravenous pamidronate and high-dose oral steroids (see Figure 1 ). As an outpatient she was prescribed oral clodronate and prednisolone 20 mg. She did not tolerate cellulose sodium phosphate. Despite initial benefit from bisphosphonate therapy, after 4 months' treatment her renal function had deteriorated with a serum creatinine of 535 5 mol/L; adjusted calcium was 2.92 mmol/L. Hydroxychloroquine was started as an adjunct to systemic corticosteroids. The first three months on this regimen showed some improvement, but adjusted calcium then increased and her renal function continued to deteriorate. Serum ACE and 1,25 dihydroxy vitamin D were measured over fourteen months (Figure 1) .
Renal dialysis, added to the corticosteroid and hydroxychloroquine treatment in October 1995, improved her general wellbeing and reduced her adjusted serum calcium concentration (2.68 mmol/L, February 1996). However, during this period she was found to have cervical carcinoma, from which she died at the age of 35 years.
COMMENT Hypercalcaemia in sarcoidosis usually improves with prednisolone though sustained therapy may be necessary to suppress 1,25(OH)2D levels and maintain normocalcaemia . It attacks several mechanisms calcium absorption, calcium reabsorption, calcium excretion, 1,25 vitamin D and osteoclast/blast function. Clodronate held the calcium around 3.00 mmol/L but did not prevent deterioration of renal function. Both chloroquine and prednisolone depress 1,25 vitamin D production. However, 1,25 vitamin D production was highest during this combination of therapy, possibly because of the summer weather. Retrospectively, it might have been worth trying 3-monthly intermittent courses of intravenous pamidronate, which would also have ensured that the patient received the therapy; but the poor renal function could have limited its use.
Why were we unable to control calcium levels and maintain renal function? Non-compliance is a strong possibility. Despite long-term treatment with high-dose steroids the patient never became cushingoid. 'Escape' from the benefits of each therapy is another.
